文献速递消化内镜消化道肿瘤与早癌

韩国人群1L PEG+抗坏血酸与2L PEG+抗坏血酸分次肠道准备疗效与安全性比较

Efficacy and safety of split-dose bowel preparation with 1 L polyethylene glycol and ascorbate compared with 2 L polyethylene glycol and ascorbate in a Korean population: a phase IV, multicenter, randomized, endoscopist-blinded study.
PubMed 文献 · Gastrointest Endosc · 2021-10-12

这项在韩国9家医院开展的多中心、内镜医师盲法、随机IV期研究,比较了1L PEG制剂Plenvu与2L PEG+抗坏血酸分次肠道准备。Plenvu组整体肠道清洁成功率非劣于2L PEG组(93.10% vs 91.86%),且整体和右半结肠高质量清洁成功率更高,息肉检出率更高,但不良事件发生率略高,大多轻微。

要点

  • Plenvu整体清洁成功率非劣于2L PEG+抗坏血酸(93.10% vs 91.86%)。
  • Plenvu整体和右半结肠高质量清洁成功率均显著更高。
  • Plenvu息肉检出率更高,但腺瘤检出率无差异,不良事件多轻微。

核心结论

  • 在韩国人群中,1L PEG+抗坏血酸分次肠道准备的整体清洁成功率非劣于2L PEG+抗坏血酸,且高质量清洁和息肉检出率更优。

研究设计与样本

  • 多中心、内镜医师盲法、随机IV期研究,韩国9家医院共纳入360例接受结肠镜检查的患者,清洁疗效分析集346例(Plenvu组174例,2L PEG组172例)。

主要发现

  • 整体肠道清洁成功率Plenvu组93.10% vs 2L PEG组91.86%,差异1.24%,单侧97.5%置信下限-4.31%,非劣效P<.0001,优效P=.661。
  • 整体高质量清洁成功率Plenvu组49.43% vs 2L PEG组37.79%(P=.029),右半结肠高质量清洁成功率60.92% vs 48.84%(P=.024)。
  • 息肉检出率Plenvu组48.85% vs 2L PEG组37.79%(P=.038),腺瘤检出率24.71% vs 20.35%(P=.331)。
  • 治疗中出现的不良事件Plenvu组65.71% vs 2L PEG组52.91%(P=.015),85.55%为轻度,99.23%的患者无需处理即恢复。

关键数值与推荐

  • 整体肠道清洁成功定义为所有结肠节段BBPS评分≥2;高质量清洁定义为整体BBPS评分=9或节段BBPS评分=3。

临床怎么用

  • 在亚洲人群中,可考虑使用1L PEG+抗坏血酸分次方案进行肠道准备,以提高高质量清洁和息肉检出。
  • 需关注Plenvu组不良事件发生率略高,但多为轻度且无需处理。

局限性

  • 研究仅纳入韩国人群,结论外推至其他亚洲人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The 1-L polyethylene glycol (PEG)-based bowel preparation agent NER1006 (Plenvu; Norgine, Harefield, UK) has shown high cleansing efficacy and tolerability in clinical trials in Europe and North America. However, no clinical trials have yet been reported in Asia. Therefore, the aim of this study was to evaluate the efficacy and safety of 1L PEG-based bowel preparation with Plenvu compared with 2L PEG plus ascorbate bowel preparation in a Korean population. METHODS: In this multicenter, endoscopist-blinded, randomized study, patients at 9 hospitals in South Korea undergoing colonoscopy received either Plenvu or 2L PEG + ascorbate (2L PEG) with a split dose. The primary endpoint was overall bowel cleansing success (Boston Bowel Preparation Scale [BBPS] score ≥2 for all segments of the colon). Secondary endpoints were high-quality bowel cleansing success (overall, BBPS score = 9; segmental colon, BPPS score = 3), polyp detection rate (PDR), and adenoma detection rate (ADR). RESULTS: Of 360 included patients, cleansing efficacy was analyzed in 346 (Plenvu, 174; 2L PEG, 172). The Plenvu group showed noninferior bowel cleansing success rates compared with 2L PEG (93.10% vs 91.86%; difference, 1.24%; 1-sided 97.5% lower confidence limit, -4.31%; Pnoninferiority < .0001; Psuperiority = .661). The Plenvu group had higher high-quality bowel cleansing success rates for overall and right-sided colon segments than the 2L PEG group (49.43% vs 37.79% [P = .029] and 60.92% vs 48.84% [P = .024], respectively). The PDR was greater with Plenvu than with 2L PEG (48.85% vs 37.79%, P = .038). However, ADR did not differ between the 2 groups (24.71% vs 20.35%, P = .331). Although treatment-emergent adverse events (TEAEs) were slightly higher in the Plenvu group than in the 2L PEG group (65.71% vs 52.91%, P = .015), most TEAEs were mild (85.55%) and most patients recovered without any management (99.23%). CONCLUSIONS: Plenvu showed noninferior overall bowel cleansing success rates comparable with 2L PEG but greater high-quality bowel cleansing in overall and right-sided colon, which might help improve the PDR in the Asian population. (Clinical trial registration number: KCT0005894.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Hong SN, Lee CK, Im JP, et al. Efficacy and safety of split-dose bowel preparation with 1 L polyethylene glycol and ascorbate compared with 2 L polyethylene glycol and ascorbate in a Korean population: a phase IV, multicenter, randomized, endoscopist-blinded study. Gastrointest Endosc. 2021. PMID: 34653425. doi:10.1016/j.gie.2021.09.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。